A randomized, 24-week, open-label, 2-arm parallel-group, multicenter study comparing the efficacy and safety of insulin glargine/lixisenatide fixed ratio combination versus insulin glargine on top of metformin in type 2 diabetic patients

Trial Profile

A randomized, 24-week, open-label, 2-arm parallel-group, multicenter study comparing the efficacy and safety of insulin glargine/lixisenatide fixed ratio combination versus insulin glargine on top of metformin in type 2 diabetic patients

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs Insulin-glargine/lixisenatide (Primary) ; Insulin glargine; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 09 Jun 2016 Results published in the Diabetes Care
    • 09 Jun 2015 Results of a post-hoc analysis to determine whether the risk of symptomatic hypoglycaemia is affected by reductions in HbA1c presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
    • 03 Jun 2015 Additional results will be presented at the 75th Scientific Sessions of the American Diabetes Association (ADA), according to a Zealand Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top